Additional Relevant Details In a poster presentation at eECE, Crinetics will report results from a Phase 1 study showing that paltusotine provided a favorable mean oral bioavailability of 70%. In addition, no abundant circulating metabolites of paltusotine were identified. Adverse events associated with paltusotine were generally mild and transient and were consistent with those reported with other somatostatin agonists. The results of this study suggest that paltusotine exhibits excellent properties appropriate for chronic once-daily oral treatment of patients with acromegaly.In April 2020, Crinetics reported interim results from an exploratory analysis of the first 13 patients who entered the ACROBAT Edge Phase 2 trial on octreotide or lanreotide depot monotherapy, which showed that, as of the cutoff date, switching to once daily oral paltusotine maintained IGF-1 levels at those achieved with prior depot therapy. Paltusotine was well tolerated and the adverse events observed were similar to those of other somatostatin agonists. No discontinuations due to drug-related adverse events occurred, and the most common treatment-emergent adverse events (>10%) were headache, arthralgia, peripheral swelling, back pain and hyperhidrosis.